aTyr Pharma, Inc.(US:ATYR) Newsfile·2025-11-12 21:44Core Points - A class action securities lawsuit has been filed against aTyr Pharma, Inc. to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [2][3] - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper off steroid usage [3][4] - The stock price of aTyr fell dramatically by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [5][4] Case Details - The complaint alleges that the defendants made overwhelmingly positive statements while concealing material adverse facts about the drug's efficacy [3] - The disappointing results of the EFZO-FIT study were disclosed during an investor call on September 15, 2025, where it was revealed that the study did not meet its primary endpoint [4] Next Steps - Shareholders who suffered losses during the relevant time frame are encouraged to seek information about their rights to recovery [6] - There is no cost or obligation for shareholders to participate in the recovery process [6] Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [7] - The firm has been consistently ranked among the top securities litigation firms in the United States [7]